No­var­tis adds opthal­mol­o­gy buy­out in year-end deal spree; Tesaro gets a speedy FDA re­view for ni­ra­parib

No­var­tis is en­gaged in a year-end deal run, it seems. On Tues­day morn­ing the phar­ma gi­ant fol­lowed up its Cona­tus pact with news that it is buy­ing Fort Worth-based En­core Vi­sion af­ter the biotech scored some pos­i­tive ear­ly-stage da­ta on their lead drug for pres­by­opia — a vi­sion dis­or­der that caus­es an in­abil­i­ty to fo­cus up close — boost­ing their oph­thal­mol­o­gy pipeline. None of the terms were dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.